*GNAL* (OMIM \#615073) mutations have recently been identified as responsible for primary dystonia \[[@b1-jmd-19006]\]. The *GNAL* mutation typically presents as adult onset (mean 32 years) craniocervical dystonia. Focal or segmental dystonia has also been reported, but generalized dystonia is relatively rare \[[@b1-jmd-19006]\]. Deep brain stimulation (DBS) is an important therapeutic strategy for patients with dystonia who are unsuccessfully treated with medication or botulinum toxin injections. The efficacy and safety of globus pallidus interna (GPi) DBS has been well established for generalized or segmental primary dystonia in previous trials \[[@b2-jmd-19006]\]. However, treatment for patients with the *GNAL* mutation has not been studied, and the efficacy and safety of DBS for these patients is not yet known. We reviewed previous reports of patients with the *GNAL* mutation who underwent GPi-DBS and reported the case of a patient with generalized dystonia due to the *GNAL* mutation who was successfully treated with bilateral GPi-DBS.

MATERIALS & METHODS
===================

Patient and molecular genetic diagnosis using next-generation sequencing
------------------------------------------------------------------------

We provide the first report of a Korean patient genetically confirmed to have the *GNAL* mutation by using next-generation sequencing. Genomic DNA was extracted from a patient blood sample. Whole exome sequencing (WES) was performed as follows. First, raw data were filtered for splice sites of known target genes and nonsynonymous coding regions related to dystonia. Second, variants with a minor allele frequency \< 1% were filtered out based on population databases, including in-house and normal Korean datasets. Subsequently, strong candidates were evaluated according to American College of Medical Genetics, 2015 guidelines \[[@b3-jmd-19006]\].

Comparison with previous reports of *GNAL* treated with GPi-DBS
---------------------------------------------------------------

We obtained studies from the PubMed database (<http://www.ncbi.nlm.nih.gov/pubmed/>) and Google Scholar by searching for keywords including *GNAL*, DYT25, and deep brain stimulation. We selected patients genetically confirmed to have the *GNAL* mutation who underwent GPi-DBS. The control group was identified by searching for keywords including DYT1, DYT6, TOR1A, THAP1, deep brain stimulation, and long-term follow up. We selected a study that included both DYT1 and DYT6 patients who underwent DBS surgery and reported follow-up data for more than 2 years. We excluded studies that did not identify the clinical character of each dystonia group or only included a specific phenotype. For the selected reports, we summarized the clinical characteristics and the effectiveness of the surgery compared with DYT1 and DYT6.

Statistical analysis
--------------------

We compared the patients with the *GNAL* mutation with previous reports of patients with DYT1 and DYT6 \[[@b4-jmd-19006]\]. Group comparisons were performed with the chi-squared test or analysis of variance depending on the variable. A responder was defined as a patient who showed more than a 25% improvement in motor score on the dystonia scale \[[@b5-jmd-19006]\]. A *p* value \< 0.05 was considered statistically significant. Statistical analysis was performed with IBM SPSS (version 25.0; IBM Corp., Armonk, NY, USA) software for Windows.

Ethical approval
----------------

This study was approved by the Institutional Review Board of Samsung Medical Center, Seoul, Korea (IRB No. 2019-01-012), and the patient provided informed consent to participate.

RESULTS
=======

Clinical description and genetic findings
-----------------------------------------

A 19-year-old, right-handed male was referred with generalized dystonia from age 12. He had no perinatal problems and reached normal developmental milestones by the age 12. He had no family history of dystonia or other neurologic diseases. The dystonia started at his trunk and spread to the other parts of the body. Upon neurological examination, his trunk deviated to the right side, and he had left shoulder elevation, left torticollis, and right laterocollis. Dystonia was present in both hands, especially when straightening his arms. The patient did not show any other abnormal movements, such as parkinsonism or myoclonus. Ceruloplasmin, a 24-hour urine test for copper levels, brain MRI, and whole spine MRI were normal. Levodopa (200 mg/day), trihexyphenidyl (12 mg/day), and baclofen (20 mg/day) were not effective. Additionally, botulinum toxin was injected to treat the truncal dystonia, but this treatment had little effect on the symptoms.

Bilateral GPi-DBS surgery was performed because of the insufficient response to the medication and botulinum toxin therapy. At the pre-DBS evaluation, the Burke-Fahn-Marsden dystonia rating scale (BFMDRS) motor section was scored 30 out of 120, and the disability scale was scored 10 out of 30 ([Supplementary Video 1](#SD1-jmd-19006){ref-type="supplementary-material"} in the online-only Data Supplement). Bilateral GPi-DBS was performed with standard stereotactic and microelectrode recording techniques ([Supplementary Figure 1A](#SD3-jmd-19006){ref-type="supplementary-material"} in the online-only Data Supplement). Dystonia gradually improved after surgery. One year after surgery, the patient's symptoms were improved, the BFMDRS motor section was rated 18 out of 120 and the disability score was 8 out of 30. The BFMDRS motor section was 9, and the disability score was 5 at two years after surgery ([Supplementary Video 2](#SD2-jmd-19006){ref-type="supplementary-material"} in the online-only Data Supplement). The patient showed an approximately 70% improvement in dystonia symptoms after surgery as estimated by the BFM-DRS score (from 30 to 9).

Genetic tests for DYT1 (TOR1A) and DYT6 (THAP1) were negative. WES was performed and analyzed for known dystonia target genes, and the test revealed heterozygosity for c.1060G\>A(p. Val354Met), a missense mutation in exon 12 of the *GNAL* gene that was previously reported as a pathogenic variant ([Supplementary Figure 1B](#SD3-jmd-19006){ref-type="supplementary-material"} in the online-only Data Supplement) \[[@b6-jmd-19006]\].

Literature review of the efficacy of GPi-DBS in dystonia patients with the *GNAL* mutation
------------------------------------------------------------------------------------------

We reviewed patients with the *GNAL* mutation who underwent GPi-DBS \[[@b7-jmd-19006]-[@b10-jmd-19006]\]. A total of eight patients were evaluated, and demographic and dystonia-related information are summarized in [Table 1](#t1-jmd-19006){ref-type="table"}. Three patients had generalized dystonia, four had segmental dystonia, and one had cervical dystonia. Five patients had early follow-up clinical data and showed good responses to GPi-DBS. All four patients who had late follow-up records showed a significant reduction in the dystonia motor scale score.

Comparisons of *GNAL* patients with DYT1 and DYT6
-------------------------------------------------

Brüggemann et al. \[[@b4-jmd-19006]\] reported short- and long-term outcomes for chronic GPi-DBS in DYT1, DYT6, and non-DYT patients. We excluded non-DYT patients because the previous study did not perform a genetic test for the *GNAL* mutation. We compared the clinical characteristics and effect of GPi-DBS for *GNAL* patients with a previous study ([Table 2](#t2-jmd-19006){ref-type="table"}). Patients with the *GNAL* mutation had an older age of onset than did patients with DYT1 and DYT6 (*p* \< 0.001). Time until first DBS (*p* = 0.055) did not differ statistically. Four patients with the *GNAL* mutation were assessed with the BFMDRS, and the other three patients were assessed with the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). The baseline dystonia motor scale score did not differ in patients assessed with the BFMDRS (*p* = 0.100). Five patients in the *GNAL* group had early follow-up data, and these individuals had a higher responder rate (5/5, 100%) than did those in the DYT6 group. Patients with DYT1 also showed a higher responder rate than did patients with DYT6 (*p* = 0.047). The responder rates at late follow-up did not differ statistically among the three groups (*p* = 0.278). The decrease in the dystonia motor scale score in the *GNAL* group was 46.9% at early follow-up and 63.4% at late follow-up.

DISCUSSION
==========

This study reviewed dystonia patients with the *GNAL* mutation who underwent DBS and found that these individuals had good responses to DBS. We also reported the first genetically confirmed case of generalized dystonia with the *GNAL* mutation in a Korean patient.

The patient with the *GNAL* mutation showed a good response at early and late follow-up. Five patients with the *GNAL* mutation had data available within one year after DBS. All five patients were classified as DBS responders and had a high reduction in the dystonia motor scale score. Brüggemann et al. \[[@b4-jmd-19006]\] reported that the effect of DBS appears to be less predictable in patients with DYT6. These authors also reported that DYT6 had a lower responder rate at early follow-up and a similar responder rate at late follow-up. In our study, patients with the *GNAL* mutation had a higher response rate than did patients with DYT6 at early follow-up, and the response to DBS was sustained at late followup, similar to the response observed in the DYT1 and DYT6 groups. This result suggests that similar to patients with DYT1, bilateral GPi-DBS would be an effective treatment for patients with the *GNAL* mutation. Whether this robust effect of DBS surgery for patients with the *GNAL* mutation is due to their clinical characteristics, such as older age at onset, short time from onset to DBS, or dystonia distribution, remains uncertain. However, the genotype of dystonia patients contributes to the DBS response. In this regard, we suggest that GPi-DBS would be a good treatment option for dystonia patients with the *GNAL* mutation if they have the proper phenotype, such as cervical, craniocervical, or generalized dystonia, especially in patients who show unsatisfactory results with medication or botulinum toxin treatment.

The *GNAL* mutation was identified as causative for dystonia in 2013 \[[@b1-jmd-19006]\]. The prevalence of the *GNAL* mutation in dystonia is estimated to be less than 1% \[[@b1-jmd-19006],[@b6-jmd-19006]\]. Cervical dystonia is the most common phenotype (93%) associated with the *GNAL* mutation, followed by cranial (57%) and speech (44%) involvement \[[@b1-jmd-19006]\]. Generalized dystonia is reported to have an incidence of only 11% among *GNAL* mutations. Our patient had childhood-onset generalized dystonia, which is an unusual phenotype among patients with the *GNAL* mutation. WES revealed heterozygosity for c.1060G\>A(p.Val354Met), a missense mutation in exon 12 of the *GNAL* gene. This variant was previously reported as pathogenic in a 48-year-old male patient with familial segmental dystonia \[[@b6-jmd-19006]\]. There is a significant clinical difference between the two patients. The previous patient had a family history of dystonia and segmental dystonia (cranial-laryngeal-cervical). However, our patient had no familial history and presented with childhood onset truncal dystonia, which progressed to generalized dystonia. To date, various dystonia phenotypes, including craniocervical dystonia, focal limb dystonia, and laryngeal dystonia, have been associated with the *GNAL* mutation. Further studies are needed to determine the phenotype-genotype matching of this mutation.

This study had several limitations. Our results were based on a literature review and a reported clinical feature. Thus, limited clinical information was available. Additionally, different clinical scales were used to assess dystonia severity depending on the study. Another limitation is the possibility of publication bias, and this study included only a limited number of patients. Therefore, the results should be interpreted carefully.

In summary, bilateral GPi-DBS can be an effective treatment option for dystonia patients with the *GNAL* mutation who are resistant to medical therapy or botulinum toxin treatment.
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Supplementary Materials
=======================

The online-only Data Supplement is available with this article at <https://doi.org/10.14802/jmd.19006>.

###### Supplementary Video Legends

Video 1. Preoperative state: dystonic posture was present in both hands, cervical and trunk and was aggravated by turning or walking.

###### Supplementary Video Legends

Video 2. Postoperative state: dystonic posture improved after bilateral globus pallidus interna deep brain stimulation surgery, especially while walking.

###### Supplementary Figure 1

A fusion image of the preoperative magnetic resonance image and a postoperative computed tomography image show deep brain stimulation electrodes located bilaterally on the globus pallidus (A). *GNAL* c.1060 G\>A(p.Val354Met) (B).

###### 

Demographic and clinical characteristics of patients with the *GNAL* mutation

                                           Case 1\[[@b9-jmd-19006]\]               Case 2\[[@b9-jmd-19006]\]                         Case 3\[[@b9-jmd-19006]\]                         Case 4\[[@b7-jmd-19006]\]                          Case 5\[[@b8-jmd-19006]\]                          Case 6\[[@b8-jmd-19006]\]                        Case 7\[[@b10-jmd-19006]\]                        Case 8 (index patient)
  ---------------------------------------- --------------------------------------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------------ ------------------------------------------------- --------------------------------------------------
  Distribution                             Segmental                               Cervical                                          Generalized                                       Segmental                                          Segmental                                          Segmental                                        Generalized                                       Generalized
  Sex                                      Female                                  Male                                              Female                                            Female                                             Male                                               Female                                           Female                                            Male
  Family history                           Y                                       Y                                                 Y                                                 Y                                                  Y                                                  Y                                                N                                                 N
  Age at onset, year                       38                                      42                                                18                                                54                                                 36                                                 42                                               47                                                12
  Years until first DBS                    15                                      11                                                23                                                6                                                  19                                                 20                                               n.a                                               7
  DBS settings                             Left GPi: 0--3+, 4 V, 90 μs, 185 Hz     Left GPi-1: C+0-, 3 V, 90 μs, 125 Hz              Left GPi: C+1-, 4.5 V, 60 μs, 145 Hz              Left GPi: C+8-, 2.3 V, 120 μs, 180 Hz              Left GPi: C+1-, 2.5 V, 90 μs, 130 Hz               Left GPi-1: C+0-, 1.25 V, 60 μs, 125 Hz          n.a                                               Left GPi: C+2-, 2.5 V, 150 μs, 150 Hz
  Left GPi-2: C+1, 3 V, 90 μs, 125 Hz      Left GPi-2: C+1-, 2 V, 60 μs, 125 Hz                                                                                                                                                                                                                                                                                                                 
  Right GPi: 8--11+, 6 V, 120 μs, 185 Hz   Right GPi-1: C+1-, 3 V, 90 μs, 125 Hz   Right GPi: C+5-, 4.2 V, 90 μs, 145 Hz             Right GPi: C+0-, 2.3 V, 120 μs, 180 Hz            Right GPi: - 8+9, 2 V, 90 μs, 130 Hz               Right GPi-1: C+1-, 2.15 V, 60 μs, 125 Hz           Right GPi: C+2-, 2.5 V, 150 μs,150 Hz                                                              
  Right GPi-2: C+0-, 3 V, 90 μs, 125 Hz    Right GPi-2: C+2-, 60 μs, 125 Hz                                                                                                                                                                                                                                                                                                                     
  Dystonia Motor Scale, Preoperative       n.a                                     24^[†](#tfn2-jmd-19006){ref-type="table-fn"}^     21^[†](#tfn2-jmd-19006){ref-type="table-fn"}^     26^[\*](#tfn1-jmd-19006){ref-type="table-fn"}^     16^[\*](#tfn1-jmd-19006){ref-type="table-fn"}^     12^[\*](#tfn1-jmd-19006){ref-type="table-fn"}^   22^[†](#tfn2-jmd-19006){ref-type="table-fn"}^     30^[\*](#tfn1-jmd-19006){ref-type="table-fn"}^
  Response rate (%)                                                                                                                                                                                                                                                                                                                                                                             
   Early follow-up (1--12 months)          n.a                                     29.2^[†](#tfn2-jmd-19006){ref-type="table-fn"}^   28.6^[†](#tfn2-jmd-19006){ref-type="table-fn"}^   n.a                                                68.7^[\*](#tfn1-jmd-19006){ref-type="table-fn"}^   n.a.                                             68.2^[†](#tfn2-jmd-19006){ref-type="table-fn"}^   40.0^[\*](#tfn1-jmd-19006){ref-type="table-fn"}^
   Late follow-up (12--96 months)          n.a                                     45.8^[†](#tfn2-jmd-19006){ref-type="table-fn"}^   57.1^[†](#tfn2-jmd-19006){ref-type="table-fn"}^   80.8^[\*](#tfn1-jmd-19006){ref-type="table-fn"}^   n.a                                                n.a                                              n.a                                               70.0^[\*](#tfn1-jmd-19006){ref-type="table-fn"}^

Burke-Fahn-Marsden Dystonia Rating Scale,

Toronto Western Spasmodic Torticollis Rating Scale.

DBS: deep brain stimulation, GPi: globus pallidus interna.

###### 

Comparison of the clinical characteristics and effectiveness of DBS

                                             *GNAL*\[[@b7-jmd-19006]-[@b10-jmd-19006]\]                                                                      DYT1\[[@b4-jmd-19006]\]                                   DYT6\[[@b4-jmd-19006]\]                                   *p* value
  ------------------------------------------ --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------
  No. of patients                            8                                                                                                               9                                                         8                                                         
  Distribution generalized/segmental/focal   3/4/1                                                                                                           8/0/1                                                     5/3/0                                                     0.143^[‡](#tfn5-jmd-19006){ref-type="table-fn"}^
  Male/female                                3/5                                                                                                             3/6                                                       7/1                                                       0.051^[‡](#tfn5-jmd-19006){ref-type="table-fn"}^
  Family history positive/negative/unknown   6/2/0                                                                                                           5/4/0                                                     4/3/1                                                     0.551^[‡](#tfn5-jmd-19006){ref-type="table-fn"}^
  Age at onset (year)                                                                                                                                                                                                                                                            
   Mean (SD)                                 36.4 (13.8)                                                                                                     11.2 (6.6)                                                10.0 (3.3)                                                \< 0.001^[§](#tfn6-jmd-19006){ref-type="table-fn"}^
   Range                                     14-- 54                                                                                                         2--23                                                     6--15                                                     
  Years until first DBS                                                                                                                                                                                                                                                          
   Mean (SD)                                 14.4 (6.6)                                                                                                      20.1 (11.1)                                               27.0 (10.8)                                               0.055^[§](#tfn6-jmd-19006){ref-type="table-fn"}^
   Range                                     6--23                                                                                                           5--41                                                     11--46                                                    
  Dystonia scale, preoperative                                                                                                                                                                                                                                                   
   Motor, mean (SD)                          21.0 (8.4)^[\*](#tfn3-jmd-19006){ref-type="table-fn"}^, 22.3 (1.5)^[†](#tfn4-jmd-19006){ref-type="table-fn"}^   43.8 (30.7)^[\*](#tfn3-jmd-19006){ref-type="table-fn"}^   37.0 (15.9)^[\*](#tfn3-jmd-19006){ref-type="table-fn"}^   0.100^[§](#tfn6-jmd-19006){ref-type="table-fn"}[ǁ](#tfn7-jmd-19006){ref-type="table-fn"}^
  Responder rate motor BFMDSR, n (%)                                                                                                                                                                                                                                             
   Early follow-up (1--16 months)            5/5 (100)                                                                                                       7/7 (100)                                                 4/7 (57.1)                                                0.047^[‡](#tfn5-jmd-19006){ref-type="table-fn"}^
   Late follow-up (22--96 months)            4/4 (100)                                                                                                       5/8 (62.5)                                                6/7 (85.7)                                                0.278^[‡](#tfn5-jmd-19006){ref-type="table-fn"}^
  Reduction of dystonia scale (%)                                                                                                                                                                                                                                                
   Early follow-up (1--16 months)            46.9                                                                                                            60                                                        32                                                        n.a
   Late follow-up (22--96 months)            63.4                                                                                                            44                                                        42                                                        n.a

Burke-Fahn-Marsden Dystonia Rating Scale (BFMDSR),

Toronto Western Spasmodic Torticollis Rating Scale,

statistical analysis was performed with chi-square test,

statistical analysis was performed with analysis of variance,

comparison of the patients who were assessed by the BFMDSR.

DBS: deep brain stimulation.

[^1]: This authors contributed equally to this work.
